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Here we describe our five years experience on use of oral hydroquinidine (HQ) in a newborn with 
familiar Short QT Syndrome (SQTS).  
In July 2005 a female child with history of SQTS in her family was born in Turin, Italy. She was 
the first-born daughter of a patient with SQTS and history of syncope during exertion and 
paroxysmal atrial fibrillation since 20 years of age, belonging to a family with many cases of 
sudden death in four generations and also in the newborn [1]. The family was genotyped and a mis-
sense mutation causing the substitution of asparagine for a positively charged lysine at codon 588 
(N588K) in the S5-loop region of the cardiac KV11.1
*
 channel KCNH2 (HERG) was found [2]. The   
effect of the mutation is to increase the repolarizing currents active during the early phase of the 
action potential, leading to abbreviation of the action potential and thus to abbreviation of the QT 
interval. Moreover it reduces the affinity of the channel for drugs with KIR blocking action, such as 
sotalol, but to a lesser degree for hydroquinidine [3,4]. 
Twelve-lead standard electrocardiogram (ECG) recordings was obtained at birth and was consistent 
with the diagnosis (QTc 310 msec). During the first two weeks of life ECG recordings was repeated 
every two days. After discharge from hospital, ECG was repeated at each ambulatory follow up 
(Figure 1). Periodically ambulatory ECG monitoring (24 hours Holter) was also performed. 
She was recognized as being affected by the N588K mutation in KCNH2 (HERG), already 
identified in the father and in other family members. 
Antiarrhythmic prophylaxis with oral HQ was started at nine days of age. Drug dosage was 
increased every week, monitoring ECG and plasma level of basal HQ (quantified by HPLC-UV). 
The target was a QTc interval at ECG  360 msec and HQ basal plasma level between 0.6 and 2.0 
g/ml (therapeutic range referred from literature). Initial oral drug dosage was 4 mg/kg three times 
daily, while maximum dosage administered to maintain HQ in therapeutic range was 10.9 mg/kg 
three times daily. The mean HQ plasma level achieved was 0.66 g/ml ± 0.23 (range 0.27-1.14). 
HQ dosage pro kg, QTc and HQ plasma levels are summarized in Table 1. A significant correlation 
between HQ plasma levels and prolongation of QT interval was observed. No correlation was found 
between HQ plasma levels and drug dosage.   
No cardiac symptoms or major side effect were observed during a follow up of five years. Only 
transient abdominal pain was observed for a few days after every increase of drug dosage. During 
periodical Holter monitoring no arrhythmic events were recorded.  
SQTS is a rare, recently recognized genetic anomaly [5], characterized by a typical 
electrocardiogram (ECG) pattern and the risk of major, sometimes lethal, arrhythmias. The ECG 
shows a short QTc interval (less than 320 msec), with lack of adaptation during increase of heart 
rate. Arrhythmias associated with SQTS are atrial fibrillation and ventricular tachyarrhythmias. 
Sudden cardiac death occurs in adult patients and also in infancy, so SQTS is a potential cause of 
Sudden Infant Death Syndrome. 
To date less then eighty patients with SQTS are described in literature and most of them are familiar 
forms. In 2000 a family (a 17-year-old girl with several episodes of paroxysmal atrial fibrillation, 
her brother, and their mother) with QT and QTc intervals < 300 ms was described [5]. In 2003 the 
short QT syndrome was recognized as a new clinical entity related to familial sudden death [1]. 
Cardiac arrest is the most frequent clinical presentation. SQTS was soon recognized as a genetic 
disorder with autosomal dominant inheritance. Gain of function mutations in three different genes 
(KCNH2, KCNQ1, KCNJ2) encoding  potassium channels and loss of functions mutations in two 
genes encoding the CaV1.2
*
 calcium channel (CACNA1C and CACNB2b), have been  linked with 
SQTS [6,7].  
Because of the high incidence of sudden death, the first-choice therapy in adult patients with SQTS 
is an implantable cardioverter-defibrillator device (ICD) [8]. In paediatric patients there are 
technical problems and risk of complications linked to ICD implant: in small babies ICD implant is 
not feasible, so pharmacological prophylaxis is the only alternative. Medical treatment proposed for 
SQTS is oral HQ, the only antiarrhythmic drug able to normalize the QT interval at resting heart 
rates [3,4,9].  
HQ therapy may induce many different adverse effects both cardiac and not. Thus, monitoring of its 
plasma levels in treated patients may be useful to avoid toxicity. Up to now data about therapeutic 
HQ monitoring in patients are rarely available in literature, even less about paediatric patients. 
The case of this infant well explains why therapeutic drug monitoring is considered an important 
tool in clinical practice in different disciplines. In newborn babies is often difficult to obtain an 
ECG with heart rate less than 100 beats/min and the correct QT evaluation is not always reliable. So 
it seems to be strategical to avoid an erroneous HQ dosage by monitoring drug plasma 
concentration. An increase in drug biotransformation ability reached by liver during the first months 
of life is probably responsible for the need of greater doses of HQ for maintaining therapeutic 
plasma concentrations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Channels nomenclature conforms to BJP’s Guide: Alexander SPH, Mathie A, Peters JA (2009). 
Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol158 (Suppl. 1): S1–S254. 
References 
 
1. Gaita F, Giustetto C, Bianchi F, Wolpert C, Schimpf R, Riccardi R, Grossi S, Richiardi E, 
Borggrefe M. Short QT syndrome. A familial cause of sudden death. Circulation 2003;108:965-
70. 
2. Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M, Menendez TM, Brugada J, 
Pollevick GD, Wolpert C, Burashnikov E, Matsuo K, Wu YS, Guerchicoff A, Bianchi F, 
Giustetto C, Schimpf R, Brugada P, Antzelevitch C. Sudden death associated with short-QT 
syndrome linked to mutations in HERG. Circulation 2004;109:30-5. 
3. Gaita F, Giustetto C, Bianchi F, Schimpf R, Haissaguerre M, Calò L, Brugada R, Antzelevitch C, 
Borggrefe M, Wolpert C. Short QT Syndrome: Pharmacological Treatment. J Am Coll Cardiol 
2004;43:1494–1499. 
4. Wolpert C, Schimpf R, Giustetto C, Antzelevitch C, Cordeiro J, Dumaine R, Brugada R, Hong 
K, Bauersfeld U, Gaita F, Borggrefe M. Further insights into the effect of quinidine in short QT 
syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol 2005;16:54–8. 
5. Gussak I,  Brugada P,  Brugada J,  Wright RS,  Kopecky SL,  Chaitman BR,  Bjerregaard P.  
Idiopathic short QT interval: a new clinical syndrome? Cardiology 2000;94:99-102. 
6. Hong K,  Piper DR,  Diaz-Valdecantos A,  Brugada J,  Oliva A,  Burashnikov E,  Santos-de-Soto 
J,  Grueso-Montero J,  Diaz-Enfante E,  Brugada P,  Sachse F,  Sanguinetti MC,  Brugada R. De 
novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero. 
Cardiovascular Research 2005;68:433-40. 
7. Hedley PL, Jørgensen P, Schlamowitz S, Wangari R, Moolman-Smook J, Brink PA, Kanters JK, 
Corfield VA, Michael Christiansen M. The Genetic Basis of Long QT and Short QT Syndromes: 
A Mutation Update. Human Mutation  2009;30:1486-511. 
8. Gaita F, Giustetto C, Mazzanti A. Short QT sindromes. Card Electrophysiol Clin 2010;2:551-8.       
9. Borggrefe M,  Wolpert C,  Antzelevitch C,  Veltmann C,  Giustetto C,  Gaita F,  Schimpf R. 
Short QT syndrome. Genotype-phenotype correlations. Journal of Electrocardiology 2005;38:75-
80.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1 
Representative twelve-lead ECGs at birth (A), at one year of age (B) and at five years (C). QTc at 
birth 310 ms (A), at one year 390 ms (B), at five years 400 ms (C), paper speed 25mm/s. 
 
 
 
 
 
 
 
 
 
 
Table 1 
Hydroquinidine (HQ) dosage, plasma concentrations and QTc measurements 
Age  
(months) 
HQ dosage 
(mg/kg) 
HQ Plasma level  
(g/ml) 
QTc  
(ms) 
0.5 4 - 310 
1  4 0.725 430 
4 5 0.267 340 
4.5 5.8 0.751 370 
7 8 0.335 340 
7.5 8.5 0.640 360 
12 8.3 0.475 390 
15 9 0.480 370 
17 10 0.777 400 
24 10.9 0.685 380 
27 9.2 1.142 420 
38 10 0.708 430 
51 9.5 0.761 400 
60 8.5 0.861 420 
 
